Abstract: The present invention describes methods of using terminal-phosphate-labeled nucleotides in the presence of a manganese salt to enhance their substrate properties towards various enzymes. Particularly described are methods of detecting a nucleic acid in a sample, based on the use of terminal-phosphate-labeled nucleotides as substrates for nucleic acid polymerases, in the presence of a manganese salt. Further provided are manganese complexes of terminal-phosphate-labeled nucleotides as well as terminal-phosphate-labeled nucleotides with new linkers with enhanced substrate properties.
Type:
Grant
Filed:
February 5, 2004
Date of Patent:
July 1, 2008
Assignee:
GE Healthcare Bio-Sciences Corp.
Inventors:
Shiv Kumar, Mark McDougall, Anup Sood, John Nelson, Carl Fuller, John Macklin, Paul Mitsis
Abstract: The present invention relates to a method of separating antibodies from contaminants in a solution, which method comprises contacting the solution with a chromatography resin comprised of a support to which multi-modal ligands have been immobilised, wherein a multi-modal ligand comprises at least one cation-exchanging group and at least one aromatic or heteroaromatic ring system. In one embodiment, the ring-forming atoms of the aromatic or hereoaromatic entity are selected among C, S or O, and the cation exchanging group is a weak cation exchanger. The present method may be used as a single step procedure or as a polishing step following a capture on a Protein A column.
Type:
Grant
Filed:
February 24, 2005
Date of Patent:
June 10, 2008
Assignee:
GE Healthcare Bio-Sciences AB
Inventors:
Bo-Lennart Johansson, Hans J. Johansson, Anders Ljunglöf, Jean-Luc Maloisel, Nicolas Thevenin
Abstract: A method of determining kinetic parameters for a reversible molecular interaction between a ligand immobilized to a solid support surface and a binding partner to the ligand in solution, comprises sequentially, without intermediate regeneration or renewal of the immobilized ligand, flowing a plurality of fluid volumes containing different known concentrations of the binding partner over the solid support surface, monitoring the momentary amount of binding partner bound to the solid support surface related to time and solution concentration of binding partner and collecting the binding data, and determining the kinetic parameters by globally fitting a predetermined kinetic model for the interaction between the binding partner and the immobilized ligand to the collected binding data, which model allows for mass transport limitation at the solid support surface.
Type:
Grant
Filed:
June 4, 2004
Date of Patent:
May 13, 2008
Assignee:
Biacore AB
Inventors:
Robert Karlsson, Karl Andersson, Christina Wass
Abstract: The present invention relates to a method of isolating fully thioated single stranded antisense oligonucleotides from a biological solution, which method comprises the steps of contacting the biological solution with an immobilised metal ion adsorption chromatography (IMAC) resin to adsorb the antisense oligonucleotides to the resin and subsequently contacting the resin with an eluent under conditions that provide desorption of the antisense oligonucleotides from the resin, wherein the fully thioated antisense oligonucleotides are separated from incorrectly thioated antisense oligonucleotides in the solution. The invention also relates to the use of an immobilised metal ion adsorption chromatography (IMAC) resin for isolation of fully thioated single stranded antisense oligonucleotides from a biological solution.
Abstract: A separation material characterized by supporting, in its surface, a linear or crosslinked stimulus responsive polymer to which a substance A having specific affinity for a target substance and a low-molecular substance B having specific affinity for the substance A have been bonded. Such a separation material can increase the recovery of a target substance to be purified and do not require desalting and hapten sugar-eliminating operations and, in addition, have high productivity.
Abstract: The present invention is a method of separating recombinant human serum albumin (rHSA) from low molecular weight contaminants in a liquid, which method comprises the steps of: (a) providing a separation medium, which includes anion-exchanging ligands coupled to a base matrix; and (b) contacting the liquid with the separation medium to adsorb the rHSA to the ligands. In one embodiment, the functional groups of the ligands are weak anion-exchanging groups, preferably secondary amines, and the density of ligands on the base matrix is relatively high.
Abstract: The present invention is a process of manufacture of one or more polysaccharide beads, comprising generating an aerosol of an aqueous polysaccharide solution, cooling the droplets of said aerosol in air to initiate gelling thereof and collecting droplets as gelled beads in a liquid or on a surface, characterised by adding a hydrophilic vapour pressure-lowering agent to said polysaccharide solution.
Type:
Grant
Filed:
April 17, 2003
Date of Patent:
March 11, 2008
Assignee:
GE Healthcare Bio-Sciences AB
Inventors:
Ralf Göran Andersson, Hans Berg, Ingemar Jonsson, Anders Larsson
Abstract: Disclosed are new quinacridone dye derivatives having characteristic fluorescence lifetimes. Also disclosed are methods for labelling target biological materials employing the quinacridone dyes and use of the labelled materials in biological assays.
Abstract: A composition comprising colloidal Fe3O4 particles coated with streptavidin is disclosed. These particles can be used in a method for separating biotinylated compounds from a solution in which the biotinylated compounds bind to the streptavidin-coated particles which are attracted to a surface by a magnet. Also disclosed is a method for making said streptavidin-coated composition, said method comprising the steps of forming colloidal Fe3O4 particles by mixing aqueous FeCl2 with aqueous FeCl3, adding aliquots of the mixture to an alkaline solution and adding streptavidin.
Abstract: The present invention relates to a method of preparing a separation medium starting with an aqueous solution of spherical and preferably functionalised primary particles of defined size, comprising the following steps: a) inverse suspension dispersing said aqueous solution of primary particles as droplets in oil; b) evaporation to remove said aqueous solution and fusion between particles to form spherical aggregates; c) size fractionation of aggregates from step b); and optionally d) repeating steps a) to c) an optional number of times to form progressively larger spherical aggregates. The invention also relates to a separation medium produced by this method. The present separation medium can be used in chromatography in the form of essentially spherical aggregates in packed or expanded bed columns or in the form of assembled aggregates on a support for filtration purposes.
Type:
Grant
Filed:
January 13, 2006
Date of Patent:
February 19, 2008
Assignee:
GE Healthcare Bio-Sciences AB
Inventors:
David C. Sherrington, Hanna Mouaziz, Karol Lacki
Abstract: The invention relates to a method of preparing multi-modal anion-exchange ligands, which comprises providing a cyclic three-functional scaffold comprising an amine, a carbonyl and a thiol; optionally derivatisation of the amine of the scaffold to provide an anion-exchanging group and/or to protect the amine; and aminolysis to open up the derivative by adding a reagent comprising an amine coupled to a residue R in order to add said amine to the carbonyl carbon of the opened scaffold. The scaffold is advantageously homocysteine thiolactone. In one embodiment, the method comprises an additional step of immobilising the opened scaffold to a base matrix to provide a separation medium, such as a chromatography medium.
Type:
Grant
Filed:
March 5, 2004
Date of Patent:
January 22, 2008
Assignee:
GE Healthcare Bio-Sciences AB
Inventors:
Ulrika Carlsson, Jean-Luc Maloisel, Nicolas Thevenin
Abstract: The invention relates to a method of determining the binding site specificity of an analyte to a ligand having at least two different binding sites, which method comprises immobilizing the ligand to a solid support, mixing the analyte with a reversibly binding reference analyte which has a dissociation behaviour that differs significantly from that of the analyte, contacting the mixture with the ligand to determine dissociation characteristics for the mixture, and determining therefrom the binding site specificity of the analyte in relation to the reference analyte. The invention also relates to an analytical system for carrying out the method, and to a computer program, computer program product and computer system for performing the method.
Type:
Grant
Filed:
November 25, 2003
Date of Patent:
January 22, 2008
Assignee:
Biacore AB
Inventors:
Robert Karlsson, Helena Nordin, Susanna Nyberg
Abstract: The invention is a method of preparing multimodal ligands for hydrophobic interaction chromatography (HIC), which comprises providing a cyclic scaffold comprising a thiol, an amine and a carbonyl group; derivatisation of the nitrogen with a reagent to introduce a primary interaction; and aminolysis of the resulting derivative, whereby a secondary interaction is introduced next to the carbonyl; wherein at least one of the primary interaction and the secondary interaction comprises a hydrophobic group and wherein non of said interactions comprises charged groups, i.e. ion exchange ligands. The invention also encompasses a separation medium comprising such multimodal ligands immobilised to a base matrix.
Type:
Grant
Filed:
March 5, 2004
Date of Patent:
January 22, 2008
Assignee:
GE Healthcare Bio-Sciences AB
Inventors:
Bo-Lennart Johansson, Jean-Luc Maloisel, Nicolas Thevenin
Abstract: This invention presents a new cDNA amplification method. RNA is first converted to cDNA. The synthesis of cDNA can include a promoter tagged oligonucleotide, and then this cDNA is ligated to form circles (or possibly concatemers). This is then amplified using a Phi29 DNA polymerase based rolling circle and strand displacement amplification. The invention allows for RNA promoter sequences to be attached to the cDNA to facilitate additional amplification through the generation of RNA from the amplified cDNA. The resulting product can then be used to make materials for gene expression studies or other RNA analysis procedures.
Abstract: The present invention provides novel engineered derivatives of green fluorescent protein (GFP) which have an amino acid sequence which is modified by amino acid substitution compared with the amino acid sequence of wild type Green Fluorescent Protein (SEQ ID NO: 2). The modified GFPs exhibit enhanced fluorescence relative to wtGFP when expressed in non-homologous cells at temperatures above 30° C., and when excited at about 490 nm compared to the parent proteins, i.e. wtGFP. An example of a preferred protein is F64L-S175G-E222G-GFP. The modified GFPs provide a means for detecting GFP reporters in mammalian cells at lower levels of expression and/or increased sensitivity relative to wtGFP. This greatly improves the usefulness of fluorescent proteins in studying cellular functions in living cells.
Type:
Grant
Filed:
October 14, 2005
Date of Patent:
November 27, 2007
Assignee:
GE Healthcare UK Limited
Inventors:
Simon Lawrence John Stubbs, Anne Elizabeth Jones, Nigel Paul Michael, Nicholas Thomas
Abstract: The present invention relates to a method for synthesis of an acrylamide derivative, starting with dissolving a salt of a nucleophilic amine in water to form an aqueous solution and desalting said solution with a base, comprising the following steps: a) addition of dissolved activated acrylic acid derivative to said solution; b) acidification of aqueous phase; and c) extraction of said aqueous phase.
Type:
Grant
Filed:
October 18, 2004
Date of Patent:
November 13, 2007
Assignee:
GE Healthcare Bio-Sciences AB
Inventors:
Mattias Algotsson, Philippe Busson, Nicolas Thevenin